Login to Your Account



Approval Letter on Ceftobiprole Sends Basilea Shares Plunging

By Cormac Sheridan


Wednesday, March 19, 2008
Basilea Pharmaceutica AG took a heavy pounding on the Swiss Stock Exchange in Zurich Tuesday, on news that the company had received an approvable letter from the FDA in response to its new drug application filing for the cephalosporin antibiotic ceftobiprole. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription